Table of Contents Author Guidelines Submit a Manuscript
Stroke Research and Treatment
Volume 2016, Article ID 2372710, 9 pages
http://dx.doi.org/10.1155/2016/2372710
Research Article

The R18 Polyarginine Peptide Is More Effective Than the TAT-NR2B9c (NA-1) Peptide When Administered 60 Minutes after Permanent Middle Cerebral Artery Occlusion in the Rat

1School of Health Sciences, The University of Notre Dame Australia, Fremantle, WA 6160, Australia
2Western Australian Neuroscience Research Institute, Nedlands, WA 6009, Australia
3Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, WA 6009, Australia
4Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA 6009, Australia

Received 24 February 2016; Accepted 11 April 2016

Academic Editor: David S. Liebeskind

Copyright © 2016 D. Milani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Kim, E. Cahill, and N. T. Cheng, “Global stroke belt: geographic variation in stroke burden worldwide,” Stroke, vol. 46, no. 12, pp. 3564–3570, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. O. A. Berkhemer, P. S. Fransen, D. Beumer et al., “MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke,” The New England Journal of Medicine, vol. 372, no. 1, pp. 11–20, 2015. View at Publisher · View at Google Scholar
  3. B. C. V. Campbell, P. J. Mitchell, T. J. Kleinig et al., “Endovascular therapy for ischemic stroke with perfusion-imaging selection,” The New England Journal of Medicine, vol. 372, no. 11, pp. 1009–1018, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. T. G. Jovin, A. Chamorro, E. Cobo et al., “Thrombectomy within 8 hours after symptom onset in ischemic stroke,” The New England Journal of Medicine, vol. 372, no. 24, pp. 2296–2306, 2015. View at Publisher · View at Google Scholar
  5. M. Goyal, A. M. Demchuk, B. K. Menon et al., “ESCAPE trial investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke,” The New England Journal of Medicine, vol. 372, no. 11, pp. 1019–1030, 2015. View at Publisher · View at Google Scholar
  6. J. L. Saver, M. Goyal, A. Bonafe et al., “SWIFT PRIME investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke,” The New England Journal of Medicine, vol. 372, no. 24, pp. 2285–2295, 2015. View at Publisher · View at Google Scholar
  7. B. P. Meloni, A. J. Craig, N. Milech, R. M. Hopkins, P. M. Watt, and N. W. Knuckey, “The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures,” Cellular and Molecular Neurobiology, vol. 34, no. 2, pp. 173–181, 2014. View at Publisher · View at Google Scholar
  8. B. P. Meloni, L. M. Brookes, V. W. Clark et al., “Poly-arginine and arginine-rich peptides are neuroprotective in stroke models,” Journal of Cerebral Blood Flow and Metabolism, vol. 35, no. 6, pp. 993–1004, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. B. P. Meloni, D. Milani, A. B. Edwards et al., “Neuroprotective peptides fused to arginine-rich cell penetrating peptides: neuroprotective mechanism likely mediated by peptide endocytic properties,” Pharmacology and Therapeutics, vol. 153, pp. 36–54, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Milani, V. W. Clark, J. L. Cross, R. S. Anderton, N. W. Knuckey, and B. P. Meloni, “Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat stroke model,” BMC Neuroscience, vol. 17, pp. 1–8, 2016. View at Publisher · View at Google Scholar
  11. M. Aarts, Y. Liu, L. Liu et al., “Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions,” Science, vol. 298, no. 5594, pp. 846–850, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Borsellol, P. G. H. Clarkel, L. Hirt et al., “A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia,” Nature Medicine, vol. 9, no. 9, pp. 1180–1186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Cook, L. Teves, and M. Tymianski, “Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain,” Nature, vol. 483, no. 7388, pp. 213–217, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. D. J. Cook, L. Teves, and M. Tymianski, “A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates,” Science Translational Medicine, vol. 4, no. 154, Article ID 154ra133, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. D. Hill, R. H. Martin, D. Mikulis et al., “Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial,” The Lancet Neurology, vol. 11, no. 11, pp. 942–950, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Campbell, B. P. Meloni, and N. W. Knuckey, “Combined magnesium and mild hypothermia (35 °C) treatment reduces infarct volumes after permanent middle cerebral artery occlusion in the rat at 2 and 4, but not 6 h,” Brain Research, vol. 1230, pp. 258–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Campbell, B. P. Meloni, H. Zhu, and N. W. Knuckey, “Magnesium treatment and spontaneous mild hypothermia after transient focal cerebral ischemia in the rat,” Brain Research Bulletin, vol. 77, no. 5, pp. 320–322, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J. B. Bederson, L. H. Pitts, M. Tsuji, M. C. Nishimura, R. L. Davis, and H. Bartkowski, “Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination,” Stroke, vol. 17, no. 3, pp. 472–476, 1986. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Komotar, G. H. Kim, M. E. Sughrue et al., “Neurologic assessment of somatosensory dysfunction following an experimental rodent model of cerebral ischemia,” Nature Protocols, vol. 2, no. 10, pp. 2345–2347, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. “Field randomization of NA-1 therapy in early responders,” http://www.strokecenter.org/.
  21. F. X. Soriano, M.-A. Martel, S. Papadia et al., “Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand,” The Journal of Neuroscience, vol. 28, no. 42, pp. 10696–10710, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. H.-S. Sun, T. A. Doucette, Y. Liu et al., “Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat,” Stroke, vol. 39, no. 9, pp. 2544–2553, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. B. T. Bråtane, H. Cui, D. J. Cook, J. Bouley, M. Tymianski, and M. Fisher, “Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor,” Stroke, vol. 42, no. 11, pp. 3265–3270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. L. R. Srejic, W. D. Hutchison, and M. M. Aarts, “Uncoupling PSD-95 interactions leads to rapid recovery of cortical function after focal stroke,” Journal of Cerebral Blood Flow and Metabolism, vol. 33, no. 12, pp. 1937–1943, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. K. F. S. Bell, R. J. Bent, S. Meese-Tamuri, A. Ali, J. P. Forder, and M. M. Aarts, “Calmodulin kinase IV-dependent CREB activation is required for neuroprotection via NMDA receptor-PSD95 disruption,” Journal of Neurochemistry, vol. 126, no. 2, pp. 274–287, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Fan, C. M. Cowan, L. Y. J. Zhang, M. R. Hayden, and L. A. Raymond, “Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease,” The Journal of Neuroscience, vol. 29, no. 35, pp. 10928–10938, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. J. Meade, B. P. Meloni, J. Cross et al., “AP-1 inhibitory peptides are neuroprotective following acute glutamate excitotoxicity in primary cortical neuronal cultures,” Journal of Neurochemistry, vol. 112, no. 1, pp. 258–270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. W. Xu, M. Zhou, and M. Baudry, “Neuroprotection by cell permeable TAT-mGluR1 peptide in ischemia: synergy between carrier and cargo sequences,” The Neuroscientist, vol. 14, no. 5, pp. 409–414, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Vaslin, C. Rummel, and P. G. H. Clarke, “Unconjugated TAT carrier peptide protects against excitotoxicity,” Neurotoxicity Research, vol. 15, no. 2, pp. 123–126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Tu, X. Xu, L. Peng et al., “DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke,” Cell, vol. 140, no. 2, pp. 222–234, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Brittain, L. Chen, S. M. Wilson et al., “Neuroprotection against traumatic brain injury by a peptide derived from the Collapsin Response Mediator Protein 2 (CRMP2),” The Journal of Biological Chemistry, vol. 286, no. 43, pp. 37778–37792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Moutal, L. François-Moutal, J. M. Brittain, M. Khanna, and R. Khanna, “Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides,” Frontiers in Cellular Neuroscience, vol. 8, article 471, 15 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. A. V. Ferrer-Montiel, J. M. Merino, S. E. Blondelle, E. Perez-Payà, R. A. Houghten, and M. Montal, “Selected peptides targeted to the NMDA receptor channel protect neurons from excitotoxic death,” Nature Biotechnology, vol. 16, no. 3, pp. 286–291, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. D. J. Mitchell, L. Steinman, D. T. Kim, C. G. Fathman, and J. B. Rothbard, “Polyarginine enters cells more efficiently than other polycationic homopolymers,” Journal of Peptide Research, vol. 56, no. 5, pp. 318–325, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Sinai, S. Duffy, and J. C. Roder, “Src inhibition reduces NR2B surface expression and synaptic plasticity in the amygdala,” Learning & Memory, vol. 17, no. 8, pp. 364–371, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Zhang, P. Su, P. Liang et al., “The DREAM protein negatively regulates the NMDA receptor through interaction with the NR1 subunit,” The Journal of Neuroscience, vol. 30, no. 22, pp. 7575–7586, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Brustovetsky, J. J. Pellman, X.-F. Yang, R. Khanna, and N. Brustovetsky, “Collapsin response mediator protein 2 (CRMP2) interacts with N-methyl-d-aspartate (NMDA) receptor and Na+/Ca2+ exchanger and regulates their functional activity,” The Journal of Biological Chemistry, vol. 289, no. 11, pp. 7470–7482, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. A. García-Caballero, V. M. Gadotti, P. Stemkowski et al., “The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity,” Neuron, vol. 83, no. 5, pp. 1144–1158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Fotin-Mleczek, S. Welte, O. Mader et al., “Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization,” Journal of Cell Science, vol. 118, no. 15, pp. 3339–3351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. T. W. Chu, P. M. Grant, and A. W. Strauss, “The role of arginine residues in the rat mitochondrial malate dehydrogenase transit peptide,” The Journal of Biological Chemistry, vol. 262, no. 26, pp. 12806–12811, 1987. View at Google Scholar · View at Scopus
  41. K. Zhao, G.-M. Zhao, D. Wu et al., “Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury,” The Journal of Biological Chemistry, vol. 279, no. 33, pp. 34682–34690, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. K. L. Horton, K. M. Stewart, S. B. Fonseca, Q. Guo, and S. O. Kelley, “Mitochondria-penetrating peptides,” Chemistry and Biology, vol. 15, no. 4, pp. 375–382, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Nakase, S. Okumura, S. Katayama et al., “Transformation of an antimicrobial peptide into a plasma membrane-permeable, mitochondria-targeted peptide via the substitution of lysine with arginine,” Chemical Communications, vol. 48, no. 90, pp. 11097–11099, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. M. P. Rigobello, E. Barzon, O. Marin, and A. Bindoli, “Effect of polycation peptides on mitochondrial permeability transition,” Biochemical and Biophysical Research Communications, vol. 217, no. 1, pp. 144–149, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Batandier, B. Guigas, D. Detaille et al., “The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin,” Journal of Bioenergetics and Biomembranes, vol. 38, no. 1, pp. 33–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. B. Guigas, D. Detaille, C. Chauvin et al., “Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study,” Biochemical Journal, vol. 382, no. 3, pp. 877–884, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. H. H. Szeto, S. Liu, Y. Soong et al., “Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury,” Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1041–1052, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. A. V. Birk, W. M. Chao, S. Liu, Y. Soong, and H. H. Szeto, “Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia,” Biochimica et Biophysica Acta—Bioenergetics, vol. 1847, no. 10, pp. 1075–1084, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Marshall, K. Y. Wong, C. N. Rupasinghe et al., “Inhibition of N-Methyl-D-aspartate-induced retinal neuronal death by polyarginine peptides is linked to the attenuation of stress-induced hyperpolarization of the inner mitochondrial membrane potential,” The Journal of Biological Chemistry, vol. 290, no. 36, pp. 22030–22048, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Szelechowski, A. Bétourné, Y. Monnet et al., “A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson's disease,” Nature Communications, vol. 5, article 5181, 2014. View at Publisher · View at Google Scholar
  51. C. A. Ferré, N. Davezac, A. Thouard et al., “Manipulation of the N-terminal sequence of the Borna disease virus X protein improves its mitochondrial targeting and neuroprotective potential,” The FASEB Journal, vol. 30, no. 4, pp. 1523–1533, 2016. View at Publisher · View at Google Scholar
  52. A. Cameron, J. Appel, R. A. Houghten, and I. Lindberg, “Polyarginines are potent furin inhibitors,” The Journal of Biological Chemistry, vol. 275, no. 47, pp. 36741–36749, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Fugere, J. Appel, R. A. Houghten, I. Lindberg, and R. Day, “Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences,” Molecular Pharmacology, vol. 71, no. 1, pp. 323–332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Horn, M. Pavlik, L. Dolečková, M. Baudys, and M. Mareš, “Arginine-based structures are specific inhibitors of cathepsin C. Application of peptide combinatorial libraries,” European Journal of Biochemistry, vol. 267, no. 11, pp. 3330–3336, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Anbanandam, D. C. Albarado, D. C. Tirziu, M. Simons, and S. Veeraraghavan, “Molecular basis for proline- and arginine-rich peptide inhibition of proteasome,” Journal of Molecular Biology, vol. 384, no. 1, pp. 219–227, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Kloss, P. Henklein, D. Siele et al., “The cell-penetrating peptide octa-arginine is a potent inhibitor of proteasome activities,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 72, no. 1, pp. 219–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Yang, E. Y. Estrada, J. F. Thompson, W. Liu, and G. A. Rosenberg, “Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 4, pp. 697–709, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Wojcik and M. Di Napoli, “Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy,” Stroke, vol. 35, no. 6, pp. 1506–1518, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. T. R. Doeppner, B. Kaltwasser, U. Kuckelkorn et al., “Systemic proteasome inhibition induces sustained post-stroke neurological recovery and neuroprotection via mechanisms involving reversal of peripheral immunosuppression and preservation of blood–brain–barrier integrity,” Molecular Neurobiology, 2015. View at Publisher · View at Google Scholar
  60. H.-H. Zhou, Y. Tang, X.-Y. Zhang et al., “Delayed administration of Tat-HA-NR2B9c promotes recovery after stroke in rats,” Stroke, vol. 46, no. 5, pp. 1352–1358, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. B. T. Lang, J. M. Cregg, M. A. DePaul et al., “Modulation of the proteoglycan receptor PTPσ promotes recovery after spinal cord injury,” Nature, vol. 518, 2015. View at Google Scholar